capsaicin topical liquid (NGX-1998) / Astellas, Acorda - LARVOL DELTA

Acorda Therapeutics announces acquisition of two neuropathic pain assets (Acorda Press Release) - "Acorda Therapeutics...announced that it has acquired two neuropathic pain management assets from NeurogesX...Qutenza® is approved by the U.S. Food and Drug Administration (FDA) for the management of neuropathic pain associated with postherpetic neuralgia. The Company also acquired NP-1998, a Phase 3 ready, prescription strength capsaicin topical solution, being assessed for the treatment of neuropathic pain. NP-1998 was previously referred to as NGX-1998."

Licensing / partnership • Pain

NeurogesX reports second quarter 2012 results (Globenewswire) - NeurogesX seeking partner in US and and other world markets for NGX-1998 and Qutenza; NGX-1998 P3 study expected by end of the year

Anticipated licensing / partnership • Anticipated new P3 trial • Pain

Efficacy and safety of NGX-1998, a novel topical liquid formulation of capsaicin, in patients with postherpetic neuralgia: Results of a multi-center, placebo-controlled trial (American Pain Society 31st Annual Scientific Meeting) - P2, N=164; NCT01228838; While the study was not powered to determine a statistically significant difference between the 10% and 20% formulations, a clear dose-response was observed in the primary endpoint; NGX-1998 was well-tolerated and resulted in improved outcomes on validated measures of neuropathic pain; A 5 minute application of NGX-1998 may provide a convenient option to patients with PHN that could reduce healthcare provider time

P2 data • Pain